Carl L Alden
Overview
Explore the profile of Carl L Alden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morton D, Bourcier T, Alden C
Toxicol Pathol
. 2012 Oct;
41(2):263-70.
PMID: 23076039
The ICH initiated talks in June 2012 to revise regulatory guidance for carcinogenicity assessment of pharmaceutical products, stimulated in part by a proposal called Negative for Endocrine, Genotoxicity, and Chronic...
2.
3.
Morris D, ONeil S, Devraj R, Portanova J, Gilles R, Gross C, et al.
Toxicol Pathol
. 2010 May;
38(4):606-18.
PMID: 20448081
Exposure to moderately selective p38alpha mitogen-activated protein kinase (MAPK) inhibitors in the Beagle dog results in an acute toxicity consisting of mild clinical signs (decreased activity, diarrhea, and fever), lymphoid...
4.
5.
6.
Csizmadia V, Raczynski A, Csizmadia E, Fedyk E, Rottman J, Alden C
Neurotoxicology
. 2007 Dec;
29(2):232-43.
PMID: 18155769
GT-1 murine neuronal cells exposed to an experimental proteasome inhibitor (EPI) for 24h showed increased cell death via a non-apoptotic mechanism, as assessed by TUNEL and DNA fragmentation assays. Immunofluorescence...
7.
Elrick M, Kramer J, Alden C, Blomme E, Bunch R, Cabonce M, et al.
Toxicol Pathol
. 2005 Apr;
33(1):118-26.
PMID: 15805063
Hepatic enzyme inducers such as phenobarbital are often nongenotoxic rodent hepatocarcinogens. Currently, nongenotoxic hepatocarcinogens can only be definitively identified through costly and extensive long-term, repeat-dose studies (e.g., 2-year rodent carcinogenicity...
8.
Kramer J, Curtiss S, Kolaja K, Alden C, Blomme E, Curtiss W, et al.
Chem Res Toxicol
. 2004 Apr;
17(4):463-70.
PMID: 15089088
Currently, the only way to identify nongenotoxic hepatocarcinogens is through long-term repeat dose studies such as the 2 year rodent carcinogenicity assay. Such assays are both time consuming and expensive...
9.
Morton D, Alden C, Roth A, Usui T
Toxicol Pathol
. 2002 Mar;
30(1):139-46.
PMID: 11890467
The Tg rasH2 transgenic mouse has been developed as an altemative to the lifetime mouse bioassay to predict the carcinogenic potential of chemicals. Unlike the p53+/- mouse, the Tg rasH2...